Imagene AI, headquartered in Tel Aviv, Israel, has partnered with Tokyo-based Daiichi Sankyo to apply multimodal AI for biomarker discovery and response prediction across select oncology and ADC development programs.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Imagene AI, headquartered in Tel Aviv, Israel, announced a collaboration with Tokyo-headquartered Daiichi Sankyo to advance biomarker discovery and treatment response prediction in oncology drug development. The partnership will apply multimodal artificial intelligence to analyze pathology images alongside molecular and clinical data, with the goal of informing patient selection and strengthening development decisions across translational research and clinical programs.
Under the collaboration, Daiichi Sankyo will use Imagene AI’s OI Suite platform, powered by the CanvOI foundation model, to analyze Hematoxylin and Eosin (H&E) and Immunohistochemistry (IHC) whole-slide images together with molecular and clinical data. The effort is intended to support earlier biomarker hypothesis generation, improve patient stratification, and guide oncology development programs.
The companies will also work on identifying biomarkers associated with treatment response across select antibody-drug conjugate programs. Imagene AI plans to apply its AI-driven pipelines and quantitative IHC scoring approach to evaluate target expression and support data-driven decision-making during development.
Imagene AI’s platform is supported by a proprietary real-world data lake integrating more than 3.5 million tissue samples along with omics and clinical outcomes data, which the collaboration will leverage to generate biomarker insights.
Imagene AI co-founder and CEO Dean Bitan said the collaboration reflects a shared effort to advance biomarker discovery as a driver of development success. He noted that integrating multimodal discovery with quantitative IHC scoring is intended to improve confidence in biomarker hypotheses, support companion diagnostic strategies, and better match patients to therapies most likely to benefit them.
Reference:
Imagene AI Announces Collaboration with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology. https://imagene-ai.com/press-release/imagene-ai-announces-collaboration-with-daiichi-sankyo-to-advance-multimodal-biomarker-discovery-in-oncology/
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.
